Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021GlobeNewsWire • 05/05/21
Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer CongressGlobeNewsWire • 04/21/21
Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewsWire • 03/02/21
Veru, Inc. (VERU) CEO Mitchell Steiner on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/10/21
Female Health Company The (VERU) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 02/10/21
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First QuarterGlobeNewsWire • 02/10/21
Veru's COVID-19 Drug Candidate Shows High Relative Reduction In Treatment Failures, Mortality In Mid-Stage StudyBenzinga • 02/08/21
Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress SyndromeGlobeNewsWire • 02/08/21
Will Female Health Company The (VERU) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 02/03/21